Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors

In the last decade, immunotherapy has completely changed the therapeutic armamentarium of patients with genitourinary tumors. In particular, the approval of anti-Programmed-death-1 (PD-1) agents in patients with renal cell carcinoma (RCC) and bladder cancer (BC) has increased their life expectancy, with a generally tolerated toxicity profile. On the contrary, patients with prostate cancer (PCa) seem to scarcely benefit from this strategy.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research